Asenapine hydrochlorideAtypical antipsychotic CAS# 1412458-61-7 |
2D Structure
- Cefditoren Pivoxil
Catalog No.:BCC4898
CAS No.:117467-28-4
- Cefoselis
Catalog No.:BCC4092
CAS No.:122841-10-5
- Balofloxacin
Catalog No.:BCC4892
CAS No.:127294-70-6
- Pefloxacin Mesylate Dihydrate
Catalog No.:BCC5089
CAS No.:149676-40-4
- Tinidazole
Catalog No.:BCC4866
CAS No.:19387-91-8
- Toltrazuril
Catalog No.:BCC4870
CAS No.:69004-03-1
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 1412458-61-7 | SDF | Download SDF |
PubChem ID | 49849508 | Appearance | Powder |
Formula | C17H17Cl2NO | M.Wt | 322.23 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 50 mg/mL (155.17 mM; Need ultrasonic) | ||
SMILES | CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24.Cl | ||
Standard InChIKey | FNJQDKSEIVVULU-CTHHTMFSSA-N | ||
Standard InChI | InChI=1S/C17H16ClNO.ClH/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19;/h2-8,14-15H,9-10H2,1H3;1H/t14-,15-;/m1./s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Asenapine hydrochloride Dilution Calculator
Asenapine hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.1034 mL | 15.5169 mL | 31.0337 mL | 62.0675 mL | 77.5843 mL |
5 mM | 0.6207 mL | 3.1034 mL | 6.2067 mL | 12.4135 mL | 15.5169 mL |
10 mM | 0.3103 mL | 1.5517 mL | 3.1034 mL | 6.2067 mL | 7.7584 mL |
50 mM | 0.0621 mL | 0.3103 mL | 0.6207 mL | 1.2413 mL | 1.5517 mL |
100 mM | 0.031 mL | 0.1552 mL | 0.3103 mL | 0.6207 mL | 0.7758 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Asenapine is a new atypical antipsychotic developed for the treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine shows high affinity (pKi) for numerous receptors, including the serotonin 5-HT1A (8.6), 5-HT1B (8.4), 5-HT2A (10.2), 5-HT2B (9.8), 5-HT2C (10.5), 5-HT5A (8.8), 5-HT6 (9.5), and 5-HT7 (9.9) receptors, the adrenergic α1 (8.9), α2A (8.9), α2B (9.5), and α2C (8.9) receptors, the dopamine D1 (8.9), D2 (8.9), D3 (9.4), and D4 (9.0) receptors, and the histamine H1 (9.0) and H2 (8.2) receptors. Asenapine behaves as an antagonist at all receptors.
- Btk inhibitor 1
Catalog No.:BCC4238
CAS No.:1412418-47-3
- 2-(Dimethylaminomethyl)-2-propanol
Catalog No.:BCN1774
CAS No.:14123-48-9
- Epiguajadial B
Catalog No.:BCN4075
CAS No.:1411629-26-9
- TRAP-6
Catalog No.:BCC3957
CAS No.:141136-83-6
- 12-Hydroxydodecanoic Acid
Catalog No.:BCN8405
CAS No.:505-95-3
- JNK-IN-8
Catalog No.:BCC1673
CAS No.:1410880-22-6
- Xanomeline oxalate
Catalog No.:BCC4146
CAS No.:141064-23-5
- 1-Hydroxy-2,3,4,7-tetramethoxyxanthone
Catalog No.:BCN6506
CAS No.:14103-09-4
- PACOCF3
Catalog No.:BCC7074
CAS No.:141022-99-3
- Gama-Tocotrienol
Catalog No.:BCN3720
CAS No.:14101-61-2
- Frangulin B
Catalog No.:BCC8175
CAS No.:14101-04-3
- 2-Thiouracil
Catalog No.:BCC4752
CAS No.:141-90-2
- QS-21
Catalog No.:BCC8243
CAS No.:141256-04-4
- PEPA
Catalog No.:BCC5951
CAS No.:141286-78-4
- Orobanchyl acetate
Catalog No.:BCN7779
CAS No.:1413843-71-6
- Trachelanthamine
Catalog No.:BCN2041
CAS No.:14140-18-2
- PX 12
Catalog No.:BCC2436
CAS No.:141400-58-0
- MRS 2219
Catalog No.:BCC6966
CAS No.:14141-47-0
- ABT-751 (E7010)
Catalog No.:BCC1085
CAS No.:141430-65-1
- Diosgenin glucoside
Catalog No.:BCN1250
CAS No.:14144-06-0
- Guajadial B
Catalog No.:BCN3972
CAS No.:1414455-03-0
- Rauvoyunine A
Catalog No.:BCN7002
CAS No.:1414883-81-0
- Rauvoyunine B
Catalog No.:BCN6995
CAS No.:1414883-82-1
- Aloin A
Catalog No.:BCN1042
CAS No.:1415-73-2
Novel Atypical Antipsychotics: Metabolism and Therapeutic Drug Monitoring (TDM).[Pubmed:26033329]
Curr Drug Metab. 2015;16(2):141-51.
Medicinal chemistry is continually developing and testing new drugs and drug candidates to satisfactorily address the needs of patients suffering from schizophrenia. In the last few years, some significant additions have been made to the list of widely available atypical antipsychotics. In particular, iloperidone, asenapine and lurasidone have been approved by the USA's Food and Drug Administration in 2009-10. In this paper, the most notable metabolic characteristics of these new drugs are addressed, with particular attention to their potential for pharmacokinetic interactions, and to the respective advantages and disadvantages in this regard. Moreover, current perspectives on the therapeutic drug monitoring (TDM) of the considered drugs are discussed. Since TDM is most valuable when it allows the personalisation and optimisation of therapeutic practices, it is even more interesting in the case of novel drugs, such as those discussed here, whose real impact in terms of side and toxic effects on very large populations is still unknown. Some analytical notes, related to TDM application, are included for each drug.
The Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-Analysis.[Pubmed:26467415]
Curr Neuropharmacol. 2015;13(5):681-91.
Akathisia is a troubling side effect that leads to non-adherence with antipsychotic regimens. Second generation antipsychotics (SGAs) tend to cause less akathisia than older agents but the risk still exists and rates vary between agents. Little is known about the incidence of akathisia among the newer SGAs. The purpose of this study was to conduct a meta-analysis of akathisia incidence rates for three of the newer SGAs: aripiprazole, asenapine, and lurasidone. Data were drawn from published and unpublished clinical trials comparing the drug of interest to either placebo or another SGA in adults with schizophrenia. Twenty-four studies (11 aripiprazole, 5 asenapine, and 8 lurasidone) provided incidence rates for akathisia and related nervous system events. Data showed that the relative risk (RR) of akathisia was double that of controls, with lurasidone having the highest individual RR at 2.7 [CI: 2-3.6]. Sensitivity analysis changed the RR of akathisia to less than 10%. The RR of akathisia was still elevated (1.75 [1.4-2.1]) when these drugs were compared only to actives (older SGAs). Agitation and anxiety RRs were also higher with the newer SGAs as compared to the older SGAs. Previous theory suggests antagonism of serotonin (5-HT)2A receptors may decrease akathisia risk. Expectations were that aripiprazole, asenapine and lurasidone would have a low incidence of akathisia, as all display strong antagonism at 5-HT2A. However, in this study all three had a significantly higher risk of akathisia compared to placebo or other SGAs. This suggests the pathophysiology of akathisia involves other receptors and is multifactorial.
Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy.[Pubmed:25119976]
CNS Spectr. 2014 Oct;19(5):439-48.
Insufficient treatment of psychosis often manifests as violent and aggressive behaviors that are dangerous to the patient and others, and that warrant treatment strategies which are not considered first-line, evidence-based practices. Such treatment strategies include both antipsychotic polypharmacy (simultaneous use of 2 antipsychotics) and high-dose antipsychotic monotherapy. Here we discuss the hypothesized neurobiological substrates of various types of violence and aggression, as well as providing arguments for the use of antipsychotic polypharmacy and high-dose monotherapy to target dysfunctional neurocircuitry in the subpopulation of patients that is treatment-resistant, violent, and aggressive. In this review, we focus primarily on the data supporting the use of second-generation, atypical antipsychotics both at high doses and in combination with other antipsychotics.
Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics.[Pubmed:24201235]
Clin Neuropharmacol. 2013 Nov-Dec;36(6):223-38.
Schizophrenia is a serious, chronic, and devastating mental illness with a substantial impact on psychological, physical, social, and economical areas of an individual and society. To treat such critical mental illness, a number of first-generation (typical) and second-generation (atypical) antipsychotics are currently available in the market. Despite such treatment options, most of patients with schizophrenia have a poor treatment outcome and become treatment resistant, causing continual deterioration on positive, negative, and cognitive symptoms, resulting in impairment of socio-occupational functioning. Hence, additional novel antipsychotics with better efficacy, safety, and tolerability profiles are needed to enable clinicians to diversify treatment options to improve treatment of schizophrenia. Recently, the 3 antipsychotics, including iloperidone (2009), asenapine (2009), and lurasidone (2010), have been approved by the US Food and Drug Administration. Two other atypical antipsychotics, including sertindole and blonanserin, are approved and used outside the United States for treatment of schizophrenia. Sertindole, after it has been voluntarily suspended by the manufacturer in 1998 due to its potential risk in causing cardiovascular-related death, was relaunched to the European market in 2005. More recently, blonanserin was approved in Japan (2008) and in Korea (2009) for the management of schizophrenia. Individual antipsychotic may have differential pros and cons compared with other antipsychotic in terms of efficacy, safety, tolerability, restoration of functional capacity, and economic aspect reflecting relapse prevention. The purpose of this review was to provide distinctive clinical characteristics and up-to-date of clinical trial data of the 5 novel atypical antipsychotics for the management of schizophrenia, which may deliver clinicians better understanding in the use of such atypical antipsychotics for the treatment of schizophrenia in clinical practice.
Newer antipsychotics and upcoming molecules for schizophrenia.[Pubmed:23545936]
Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509.
BACKGROUND: The management of schizophrenia has seen significant strides over the last few decades, due to the increasing availability of a number of antipsychotics. Yet, the diminished efficacy in relation to the negative and cognitive symptoms of schizophrenia, and the disturbing adverse reactions associated with the current antipsychotics, reflect the need for better molecules targeting unexplored pathways. PURPOSE: To review the salient features of the recently approved antipsychotics; namely, iloperidone, asenapine, lurasidone and blonanserin. METHODS: We discuss the advantages, limitations and place in modern pharmacotherapy of each of these drugs. In addition, we briefly highlight the new targets that are being explored. RESULTS: Promising strategies include modulation of the glutamatergic and GABAergic pathways, as well as cholinergic systems. CONCLUSIONS: Although regulatory bodies have approved only a handful of antipsychotics in recent years, the wide spectrum of targets that are being explored could eventually bring out antipsychotics with improved efficacy and acceptability, as well as the potential to revolutionize psychiatric practice.